ImmunityBio, Inc.
ImmunityBio, Inc.（IBRX）股价预测与分析师目标价
华尔街共识、12 个月目标价、模型推演与 EPS/营收预期 — 来自分析师数据与历史行情。
ibrx · 股价预测 · 5 位分析师（近3月）· FMP · 更新于 2026年6月8日
分析师评级与共识
基于过去 3 个月内 5 位华尔街分析师
Buy
5 位分析师
共识
评级分布
12 个月目标价
High
$15.00
Consensus
$13.00
+80.4% upside
Low
$12.00
Median: $12 · Last Close: $7.21
12 个月目标价预测
历史收盘价 + 分析师 12 个月目标价预测区间
Consensus Target
$13.00
80.4% upside
High Target
$15
108.2%
Low Target
$12
66.6%
Current Price
$7.21
as of today
Based on analyst price targets, the IBRX stock price prediction for the next 12 months ranges from $12 to $15. The consensus IBRX price forecast of $13.00 implies 80.4% upside from the current price of $7.21.
短期股价预测
算法生成 · 每日更新
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-09 | $6.88 | ↓ 4.47% |
1-day model range: $6.83–$6.94. Peak: $6.94 (-4.47%).
长期股价预测
基于技术分析的股价预测
14 项技术面信号（SMA×6 + EMA×6 + RSI + MACD）· EEAT 方法论透明
Market Sentiment
NEUTRAL
Based on 14 technical indicators
Refreshes daily from EOD close
Moving Averages · IBRX · Jun 8, 2026
最新分析师评级与调整
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2026-06-02 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2026-05-21 | BTIG | Maintains | Buy→Buy |
| 2026-05-20 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2026-05-05 | D. Boral Capital | Maintains | Buy→Buy |
| 2026-04-21 | D. Boral Capital | Maintains | Buy→Buy |
| 2026-04-08 | D. Boral Capital | Maintains | Buy→Buy |
| 2026-03-26 | D. Boral Capital | Maintains | Buy→Buy |
| 2026-03-23 | D. Boral Capital | Maintains | Buy→Buy |
| 2026-03-17 | D. Boral Capital | Maintains | Buy→Buy |
| 2026-03-09 | D. Boral Capital | Maintains | Buy→Buy |
Wall Street analysts have recently issued updated ratings on ImmunityBio, Inc. (IBRX) stock. Of the recent 68 rating actions, 1 were upgrades and 1 were downgrades. 5 analysts currently cover IBRX.
分析师推荐趋势
IBRX analyst recommendation trends show decreasing buy-side sentiment over the past 6 months. Buy rating actions changed from 7 to 1 per month.
财务预测：EPS 与营收一致预期
Revenue This Year
$210M
↓ 81.3% YoY
Revenue Next Year
$452M
↑ 115.6% YoY
EPS This Year
$-0.69
EPS Next Year
$-0.10
↓ 84.9% YoY
EPS ForecastReported vs Estimated
Analysts forecast IBRX EPS of $-0.69 for the current fiscal year, based on estimates from 2 analysts. The IBRX revenue forecast is $210M for the current year. These are analyst consensus estimates via FMP / S&P Global.
关于预测与目标价
IBRX 股价预测由两类独立数据源支撑：来自 5 位华尔街分析师（S&P Global / FMP）的共识评级，以及基于历史日终价计算的技术分析。IBRX 的共识目标价为 $13.00（+80.4% 上行空间），分析师共识为 Buy。
IBRX 的短期预测（明日）为 $6.88（-4.47%）。
ImmunityBio, Inc. 在 NASDAQ 上市，代码 IBRX。IBRX 在 2027 年的整体展望偏积极，在覆盖分析师中约 100% 对应 Buy 共识。
常见问题
IBRX 预测 · 8 个问题根据 5 位华尔街分析师，IBRX 的 12 个月平均目标价为 $13.00，最高 $15.00、最低 $12.00。若有图表，中位目标价可在上方查看。相对当前价 $7.21，隐含约 +80.4% 的上行空间。
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.